Loading clinical trials...
Loading clinical trials...
A Proof-of-Concept, Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Single Doses of DSM265 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-Infection Over a 35-Day-Extended Observation Period
Conditions
Interventions
DSM265 400mg
DSM265 xmg
+1 more
Locations
1
Peru
Clínica de la Asociación Civil Selva Amazónica
Iquitos, Departamento de Loreto (Amazonía Peruana), Peru
Start Date
January 1, 2016
Primary Completion Date
January 1, 2016
Completion Date
January 1, 2016
Last Updated
June 22, 2016
NCT06068530
NCT05690841
NCT05764746
NCT06549257
NCT07373301
NCT03923725
Lead Sponsor
Medicines for Malaria Venture
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions